Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceritinib + docetaxel
- Development stage
- Phase 1
- Lead developer
- Moffitt Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of ceritinib and docetaxel, currently being evaluated in a Phase I/Ib clinical trial (NCT03611738) led by the H. Lee Moffitt Cancer Center and Research Institute. Ceritinib is an oral small molecule tyrosine kinase inhibitor that primarily targets anaplastic lymphoma kinase (ALK), but also inhibits ROS1 and the insulin-like growth factor 1 receptor (IGF-1R). Docetaxel is a taxane-based chemotherapy agent that works by binding to and stabilizing tubulin, which disrupts microtubule assembly and leads to cell cycle arrest and apoptosis. The study investigates the potential of ceritinib to enhance the efficacy of docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who are ALK-negative and EGFR wild-type, a population that has progressed on platinum-based chemotherapy and for whom docetaxel is a standard but often insufficiently effective second-line treatment.
- Brand names
- Zykadia + Taxotere
- Other names
- Ceritinib plus DocetaxelCeritinib/Docetaxel
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)FAK (Focal adhesion kinase)IGF-1R (Insulin-like growth factor 1 receptor)RPS6KA1 (Ribosomal S6 kinase Alpha-1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ceritinib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceritinib + docetaxel.